Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su Zipalertinib in pazienti con carcinoma polmonare avanzato non a piccole cellule con inserzioni dell'esone 20 del recettore del fattore di crescita epidermico (EGFR) o altre mutazioni non comuni. (REZILIENT2)

5 ottobre 2026 aggiornato da: Taiho Oncology, Inc.

Uno studio di coorte multicentrico globale di fase 2b in aperto per valutare la sicurezza e l'efficacia di Zipalertinib in pazienti con carcinoma polmonare non a piccole cellule localmente avanzato o metastatico con inserzione dell'esone 20 e mutazioni non comuni/singole o composte del recettore del fattore di crescita epidermico.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study will evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound Epidermal Growth Factor Receptor Proteins Mutations (EGFRmts). The drug-drug interaction (DDI) substudy will assess the potential DDI effects of zipalertinib on the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates and transporter substrates and also evaluate the relationship between zipalertinib concentration and QT interval change from baseline. Additionally, dose optimization substudy will be conducted to confirm an optimized dose of zipalertinib monotherapy.

Participants will be enrolled into 1 of the 4 following cohorts:

  • Cohort A ("prior ex20ins treatment") will include participants harboring EGFR ex20ins who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20ins agent for their advanced disease (administered together or separately).
  • Cohort B ("first-line") will include participants harboring EGFR ex20ins who have not received prior treatment for advanced or metastatic disease and are not appropriate candidates for first-line doublet platinum-based chemotherapy or have refused first-line doublet platinum-based chemotherapy.
  • Cohort C ("active brain mets") will include participants harboring EGFR ex20ins or other uncommon single or compound EGFRmts and active brain metastases and/or leptomeningeal disease (LMD). Participants may or may not have had prior treatment for advanced disease.
  • Cohort D ("other uncommon EGFRmts") will include participants harboring other non-ex20ins, excluding C797S (uncommon single or compound) EGFRmts who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.

For DDI substudy, participants will be enrolled in two groups:

  • CYP Cocktail Group will receive a single dose of cocktail of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
  • Transporter Cocktail Group will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

For dose-optimization substudy, participants with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor protein ex20ins mutations (EGFRmts) will be randomized to receive zipalertinib at different doses with continuous daily dosing until any discontinuation criterion is met. Participants will be enrolled into two groups: Arm A and Arm B, in which they will receive different doses of zipalertinib.

Tipo di studio

Interventistico

Iscrizione (Stimato)

220

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New South Wales
      • Bankstown, New South Wales, Australia, 2200
        • Reclutamento
        • Bankstown-Lidcombe Hospital
      • Saint Leonards, New South Wales, Australia, 2065
        • Reclutamento
        • Genesis Care North Shore
    • Western Australia
      • Joondalup, Western Australia, Australia, 6027
        • Ritirato
        • Joondalup Hospital Pharmacy
      • Brampton, Canada, L6R 3J7
        • Reclutamento
        • William Osler Health System - Brampton Civic Hospital
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Corea del Sud, 10408
        • Ritirato
        • National Cancer Center - Korea
      • Suwon, Gyeonggi-do, Corea del Sud, 16499
        • Reclutamento
        • Ajou University Hospital
      • Suwon, Gyeonggi-do, Corea del Sud, 16247
        • Reclutamento
        • Saint Vincent's Hospital
    • Gyeongsangnamdo [Kyongsangnam-do]
      • Jinju, Gyeongsangnamdo [Kyongsangnam-do], Corea del Sud, 52727
        • Reclutamento
        • Gyeongsang National University Hospital
    • Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]
      • Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi], Corea del Sud, 22332
        • Reclutamento
        • Inha University Hospital
    • Jeollanam-do
      • Hwasun-gun, Jeollanam-do, Corea del Sud, 58128
        • Ritirato
        • Chonnam National University Hwasun Hospital
    • Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Corea del Sud, 05505
        • Reclutamento
        • Asan Medical Center
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Corea del Sud, 08308
        • Reclutamento
        • Korea University Guro Hospital
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Corea del Sud, 03080
        • Reclutamento
        • Seoul National University Hospital
      • Soeul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Corea del Sud, 06591
        • Ritirato
        • Seoul St. Mary's Hospital
      • Saint-Herblain, Francia, 44800
        • Reclutamento
        • Hopital Nord Laennec
    • Aslace
      • Strasbourg, Aslace, Francia, 67091
        • Ritirato
        • Nouvel Hôpital Civil
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, Francia, 69008
        • Reclutamento
        • Centre Leon Berard
    • Basse-Normandie
      • Caen, Basse-Normandie, Francia, 14033
        • Reclutamento
        • CHU Caen Normandie
    • Limousin
      • Limoges, Limousin, Francia, 87042
        • Reclutamento
        • Centre Hospitalier Universitaire Limoges
    • New Aquitaine
      • Pessac, New Aquitaine, Francia, 33604
        • Reclutamento
        • Hopital Haut Leveque
    • Provence-Alpes-Côte d'Azur Region
      • Marseille, Provence-Alpes-Côte d'Azur Region, Francia, 13015
        • Reclutamento
        • Hôpital Nord de Marseille
    • Île-de-France Region
      • Boulogne-Billancourt, Île-de-France Region, Francia, 92100
        • Reclutamento
        • Hopital Ambroise Pare
      • Paris, Île-de-France Region, Francia, 75005
        • Reclutamento
        • Institut Curie
      • Dresden, Germania, 01307
        • Reclutamento
        • Uniklinik Dresden
      • Giessen, Germania, 35392
        • Reclutamento
        • UKGM Studienzentrale
      • Regensburg, Germania, 93053
        • Ritirato
        • UKR Innere Med II Pneumologie
    • Hassen
      • Kassel, Hassen, Germania, 34125
        • Reclutamento
        • Gesundheit Nordhessen Holding AG
      • Okayama, Giappone, 700-8558
        • Reclutamento
        • Okayama University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Giappone, 464-8681
        • Reclutamento
        • Aichi Cancer Center
    • Chiba
      • Kashiwa-shi, Chiba, Giappone, 277-8577
        • Reclutamento
        • National Cancer Center Hospital East
    • Hukuoka
      • Fukuoka, Hukuoka, Giappone, 811-1395
        • Reclutamento
        • NHO Kyushu Cancer Center
    • Miyagi
      • Sendai, Miyagi, Giappone, 980-0873
        • Reclutamento
        • Sendai Kousei Hospital
    • Niigata
      • Niigata, Niigata, Giappone, 951-8566
        • Reclutamento
        • Niigata Cancer Center Hospital
    • Osaka
      • Sayama, Osaka, Giappone, 589-8511
        • Reclutamento
        • Kindai University Hospital
    • Shizuoka
      • Sunto-gun, Shizuoka, Giappone, 411-8777
        • Reclutamento
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo Ku, Tokyo, Giappone, 104-0045
        • Reclutamento
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Giappone, 135-8550
        • Reclutamento
        • Cancer Institute Hospital of JFCR
    • Hong Kong Island
      • Pok Fu Lam, Hong Kong Island, Hong Kong
        • Reclutamento
        • Queen Mary Hospital
      • Cremona, Italia, 26100
        • Reclutamento
        • Azienda Socio-Sanitaria Territoriale di Cremona
      • Milan, Italia, 20132
        • Reclutamento
        • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
      • Parma, Italia, 43126
        • Reclutamento
        • Azienda Ospedaliero-Universitaria di Parma
      • Ravenna, Italia, 48121
        • Reclutamento
        • Ospedale S. Maria delle Croci
    • Florence
      • Florence, Florence, Italia, 50134
        • Reclutamento
        • Azienda Ospedaliero - Universitaria Careggi
    • Forli-Cesena
      • Meldola, Forli-Cesena, Italia, 47014
        • Reclutamento
        • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
    • England
      • Barnet, England, Regno Unito, EN5 3DJ
        • Reclutamento
        • The Royal Free Hospital NHS Foundation Trust
      • London, England, Regno Unito, NW3 2QG
        • Reclutamento
        • Royal Free London NHS Foundation Trust
      • Manchester, England, Regno Unito, M20 4BX
        • Reclutamento
        • The Christie NHS Foundation Trust
      • Nottingham, England, Regno Unito, NG5 1PB
        • Reclutamento
        • Nottingham University Hospitals NHS Trust
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Hospital Clinic de Barcelona
      • Barcelona, Spagna, 08017
        • Reclutamento
        • UOMi Clinica Mi Tres Torres
      • Barcelona, Spagna, 08023
        • Reclutamento
        • Hospital Quirónsalud Barcelona
      • Jaén, Spagna, 23007
        • Reclutamento
        • Complejo Hospitalario de Jaen
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre
      • Madrid, Spagna, 28040
        • Reclutamento
        • Hospital Universitario Fundación Jiménez Díaz
      • Madrid, Spagna, 28046
        • Reclutamento
        • Hospital La Paz
      • Madrid, Spagna, 28033
        • Reclutamento
        • MD Anderson Cancer Center Madrid
    • Malaga
      • Málaga, Malaga, Spagna, 29010
        • Reclutamento
        • Hospital Regional Universitario de Málaga - Hospital General
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • Ritirato
        • University of Alabama at Birmingham
    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope - Duarte
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Beth Israel Deaconess Medical Center
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89169
        • Reclutamento
        • Comprehensive Cancer Centers of Nevada - Central Valley - Twain
    • New Jersey
      • Basking Ridge, New Jersey, Stati Uniti, 07920
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Basking Ridge
      • Middletown, New Jersey, Stati Uniti, 07748
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Monmouth
      • Montvale, New Jersey, Stati Uniti, 07645
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Bergen
    • New York
      • Commack, New York, Stati Uniti, 11725
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Commack
      • Harrison, New York, Stati Uniti, 10604
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Westchester
      • Long Island City, New York, Stati Uniti, 11101
        • Reclutamento
        • MSK Cancer Center
      • Uniondale, New York, Stati Uniti, 11553
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Nassau
    • Ohio
      • Canton, Ohio, Stati Uniti, 44718
        • Reclutamento
        • Gabrail Cancer and Research Center
      • Columbus, Ohio, Stati Uniti, 43219
        • Ritirato
        • Zangmeister Cancer Center
      • Toledo, Ohio, Stati Uniti, 43623
        • Ritirato
        • The Toledo Clinic Cancer Center
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Ritirato
        • SCRI Oncology Partners
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • University of Texas MD Anderson Cancer Center
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • IDS Pharmacy
      • Adana, Turchia (Türkiye), 01140
        • Reclutamento
        • Medical Park Seyhan Hastanesi
      • Edirne, Turchia (Türkiye), 22030
        • Reclutamento
        • Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi
      • Istanbul, Turchia (Türkiye), 34722
        • Reclutamento
        • Prof. Dr. Suleyman Yalcin Sehir Hastanesi
      • Istanbul, Turchia (Türkiye), 34214
        • Ritirato
        • Bagcilar Medipol Mega Universite Hastanesi
    • Istanbul
      • Esenyurt, Istanbul, Turchia (Türkiye), 34517
        • Reclutamento
        • Istinye Üniversite Hastanesi Liv Hospital Bahcesehir

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Written informed consent.

  2. ≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.

  3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

    Cohort A participants:

    • Documented EGFR ex20ins status, as determined by local testing performed at a Clinical Laboratory Improvement Amendments (CLIA) certified (United States [US]) or locally certified laboratory (outside the US).

    • Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.

      i. Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008), and BLU451. Other prior ex20ins--directed treatment may be discussed with the Sponsor for eligibility assessment.

    • Participants with brain metastasis must be neurologically stable. Participants must have received central nervous system (CNS)-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening Period. Additionally, they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with a history of uncontrolled seizures or LMD are not eligible.

    Cohort B participants:

    • Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
    • Participants who have not received prior treatment for advanced or metastatic disease and who are not appropriate candidates for first-line doublet platinum-based chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment.
    • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.

    Cohort C participants:

    • Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).

    • Presence of brain metastasis(es) characterized as at least one of the following:

      • Newly diagnosed and/or progressive brain metastasis(es) measurable by Response Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected to CNS-directed therapy, AND/OR
      • LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.
    • Participants may not require other immediate CNS-directed therapy or will likely require other CNS directed anti-tumor therapy during the first cycle of study treatment, as judged by the Investigator.

    Cohort D participants:

    • Documented other uncommon single or compound EGFR non-ex20ins status (excluding C797S), as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate document.
    • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
    • Participants who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.
    • Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment. Participants may not have received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor (TKI).
  4. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

  5. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Participants with insufficient tissue may be eligible following discussion with the Sponsor.

  6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.

  7. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.

  8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female participants are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

  9. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 1 month after the last dose of study treatment.

DDI Substudy:

  1. Participant has pathologically confirmed, locally advanced or metastatic NSCLC:

    a. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendments (CLIA) certified (US) or locally certified laboratory (outside of the US) local laboratory, defined as either one of the following EGFRmts:

    • ex20ins EGFRmt OR
    • other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) OR
    • common EGFRmt (eg, ex19del or L858R)
  2. Participant has progressed on or after receiving prior standard of care (SoC) systemic therapy for their locally advanced or metastatic NSCLC disease unless:

    • Participant for whom no approved therapy with demonstrated clinical benefit is indicated or available,
    • Participant is intolerant to the available first-line (1L) SoC treatment options, OR
    • Participant has refused 1L SoC treatment options (after being appropriately informed of the treatment options, risks, and benefits).
  3. Participants with brain metastasis are eligible if they fulfill all of the criteria below:

    • Have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by brain imaging (MRI or CT scan) during the Screening Period,
    • Are on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment,
    • Are neurologically stable with no history of uncontrolled seizures.
  4. ECOG PS of 0 or 1.

Dose Optimization Substudy:

  1. Has pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

    1. Documented EGFR ex20ins status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US)
    2. Progressed on or after systemic therapy standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.

    Note: Progression on or after systemic therapy with amivantamab is permitted (eg, given as monotherapy or in combination with chemotherapy).

  2. Participants with CNS metastases are eligible if both of the following criteria are met:

    i. Measurable lesions according to RANO-BM defined as a contrast-enhancing lesion that can be accurately measured in at least one dimension, with a minimum size of 10 millimeters (mm), or at least 5 mm if MRI slice thickness is ≤ 1.5 mm ii. Previously received definitive local treatment and have stable CNS disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) OR Asymptomatic CNS metastases ≤ 2 cm in size if, in the opinion of the investigator, immediate definitive treatment is not indicated.

  3. Measurable disease per RECIST 1.1.

  4. Has archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers

  5. ECOG PS of 0 or 1.

  6. Has adequate organ function.

Exclusion Criteria:

  1. Participant is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.

  2. Has received any of the following within the specific time frame specified:

    1. Participant has received Zipalertinib (TAS6417/CLN081) at any time
    2. CNS radiotherapy (gamma knife radiotherapy is allowed) ≤ 12 weeks, thoracic radiotherapy ≤ 28 days, or other palliative radiation ≤ 14 days prior to the first dose of study
    3. Anticancer immunotherapy ≤28 days prior to the first dose of study treatment
    4. Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.
    5. Any prior treatment with an EGFR exon20ins- targeted TKI
    6. Participants with leptomeningeal CNS disease.
  3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Participants with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.

  4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.

  5. Impaired cardiac function or clinically significant cardiac disease including any of the following:

    1. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification.
    2. Serious cardiac arrhythmias requiring treatment.
    3. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
  6. Is unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).

  7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:

    1. Adequately treated basal or squamous cell carcinoma of the skin
    2. Cancer in situ of the breast or cervix
    3. Participants with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease
    4. Participants with concurrent malignancy clinically stable and not requiring tumor-directed treatment
  8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.

  9. History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.

  10. Active bleeding disorders.

  11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.

  12. Is pregnant, lactating, or planning to become pregnant.

  13. The participant is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort A ("prior ex20ins treatment")

Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib
Sperimentale: Cohort B ("first-line treatment")

Cohort B participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib
Sperimentale: Cohort C ("active brain mets")

Cohort C participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib
Sperimentale: Cohort D ("other uncommon EGFRmts").

Cohort D participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib
Sperimentale: DDI Substudy: CYP Cocktail Group

Participants will receive a single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib

Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.

Sperimentale: DDI Substudy: Transporter Cocktail Group

Participants will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib

Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

Sperimentale: Dose Optimization Substudy: Arm A

Participants will receive zipalertinib, orally, at Arm A dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib
Sperimentale: Dose Optimization Substudy: Arm B

Participants will receive zipalertinib, orally, at Arm B dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.

Oral tablets

Altri nomi:
  • CLN-081
  • zipalertinib

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Coorti 1-4: tasso di risposta obiettivo (ORR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: ORR Valutato dalla Revisione Centrale Indipendente in Cieco (BICR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Coorte C: Tasso di risposta globale intracranico (i) (iORR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorte C: durata intracranica della risposta completa (IDCR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorte C: durata intracranica della risposta (IDOR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: numero di partecipanti con trattamento eventi avversi emergenti (TEAES) classificati secondo i criteri di terminologia comune del National Cancer Institute per eventi avversi versione 5.0 (CTCAE V5.0)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: numero di partecipanti con cambiamenti clinicamente significativi nei parametri di laboratorio clinico
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: numero di partecipanti con cambiamenti clinicamente significativi nei segni vitali
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: numero di partecipanti con cambiamenti clinicamente significativi nei parametri di elettrocardiogramma (ECG)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: numero di partecipanti con variazione nella frazione di eiezione ventricolare sinistra (LVEF) valutata mediante scansione elettrocardiografia (ECHO) e acquisizione multigata (MUGA)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: tasso di controllo delle malattie (DCR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: durata della risposta (Dor)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: sopravvivenza libera da progressione (PFS)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: sopravvivenza globale (OS)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Coorti 1-4: concentrazione plasmatica minima (CMIN) di zipalertinib
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
DDI SOUPDY: cambiamento dal basale nell'intervallo QT corretto per la frequenza cardiaca usando l'intervallo di formula di Fridericia (QTCF) dopo la somministrazione di zipalertinib nel gruppo cocktail del CYP
Lasso di tempo: Ciclo 1 (lunghezza del ciclo = 21 giorni)
Ciclo 1 (lunghezza del ciclo = 21 giorni)
DDI SOUPDY: concentrazione plasmatica massima medio geometrica (CMAX) dopo la somministrazione di dose multipla di zipalertinib nei gruppi di cocktail del gruppo CYP e trasportatore
Lasso di tempo: Ciclo 1 (lunghezza del ciclo = 21 giorni)
Ciclo 1 (lunghezza del ciclo = 21 giorni)
DDI SOUPDY: area media geometrica sotto curva (AUC) dopo la somministrazione di dose multipla di zipalertinib nei gruppi di cocktail del gruppo CYP e trasportatore
Lasso di tempo: Ciclo 1 (lunghezza del ciclo = 21 giorni)
Ciclo 1 (lunghezza del ciclo = 21 giorni)
DDI SOUPDY: numero di partecipanti con eventi avversi emergenti (Teaes) nel gruppo CYP e cocktail trasportatore
Lasso di tempo: Ciclo 1 (lunghezza del ciclo = 21 giorni)
Ciclo 1 (lunghezza del ciclo = 21 giorni)
Sottostudio di Ottimizzazione del Dosaggio: Durata della Risposta (DoR) Valutata da BICR e dallo Sperimentatore
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: Tempo di Risposta Valutato dal BICR e dallo Sperimentatore
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: Variazione Percentuale della Dimensione del Tumore rispetto al Basale Valutata da BICR e dallo Sperimentatore
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: DCR Valutata da BICR e Sperimentatore
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: PFS Valutata da BICR e dallo Sperimentatore
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: Tasso di PFS a 6 Mesi
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: ORR Valutato dallo Sperimentatore
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: Sopravvivenza Globale (OS)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: iORR (Risposta Obiettiva Intracranica) secondo i Criteri RANO-BM (Valutazione della Risposta in Neuro-oncologia per Metastasi Cerebrali)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione del Dosaggio: Durata della Risposta Intracranica (iDOR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione del Dosaggio: Tasso di Controllo della Malattia Intracranica (iDCR)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni
Sottostudio di Ottimizzazione della Dose: Numero di Partecipanti con Eventi Avversi (EA) ed Eventi Avversi Gravi (EAG)
Lasso di tempo: Fino a circa 2 anni
Fino a circa 2 anni

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

31 luglio 2023

Completamento primario (Stimato)

31 agosto 2028

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

11 luglio 2023

Primo inviato che soddisfa i criteri di controllo qualità

21 luglio 2023

Primo Inserito (Effettivo)

1 agosto 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • TAS6417-201
  • 2023-503865-48 (Numero EudraCT)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .